Value of rilmenidine therapy and its combination with perindopril on blood pressure and left ventricular hypertrophy in patients with essential hypertension (VERITAS)

Current Medical Research and Opinion

Volumn 19, Issue 3, 2003, Pages 205-217

  Farsang, Csaba ^a   Lengyel, Mária ^a,b   Borbás, Sarolta ^b   Zorándi, Ágnes ^b   Szórádi Dienes, Bernadett ^c  

^a Szent Imre Hospital   (Hungary)

^b Gottsegen Gyorgy Hung Inst C   (Hungary)

^c EGIS PHARMACEUTICALS LTD   (Hungary)

Author keywords

ACE inhibitors; Echocardiography; Essential hypertension; Imidazoline receptor agonists; Left ventricular hypertrophy; Perindopril; Rilmenidine

Indexed keywords

ANTIHYPERTENSIVE AGENT; PERINDOPRIL; RILMENIDINE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ECHOCARDIOGRAPHY; FATIGUE; FEMALE; HEADACHE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; SEXUAL DYSFUNCTION; SOMNOLENCE; VERTIGO; XEROSTOMIA;

ADRENERGIC ALPHA-AGONISTS; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; OXAZOLES; PERINDOPRIL;

EID: 0037569206     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125001659     Document Type: Article

References (81)

1. The sixth report of the Joint National Committee on Prevention, Detection, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997;157:2413-46
2. A hypertonia ellátásának szakmai és szervezeti irányelvei. A Magyar Hypertonia Társaság (Hungarian Society of Hypertension) állásfoglalása és ajánlása a Belgyógyászati Szakmai Kollégium jóváhagyásával. Hypertonia és Nephrologia 2001;5(S1):1-44
3. World Health Organization - International Society of Hypertension Guidelines of the Management of Hypertension. J Hypertens 1999;17:151-83
4. Bousquet P, Feldman J, Bloch R, Schwartz J. The nucleus reticularis lateralis: a region highly sensitive to clonidine. Eur J Pharmacol 1981;69:389-92
5. Bousquet P, Feldman J, Schwartz J. Central cardiovascular effects of alpha adrenergic drugs: differences between catecholamines and imidazolines. J Pharmacol Exp Ther 1984;230:232-6
6. Michel MC, Insel PA. Are there multiple imidazoline binding sites? Trends Pharmacol Sci 1989;10:342-4
7. 2 sites. Br J Pharmacol 1994;112:1065-70
8. Göthert M, Bruess M, Boenish H, Molderings GJ. Presynaptic imidazoline receptors: new developments in characterization and classification. Ann N Y Acad Sci 1999;881:171-84
9. Molderings GJ, Göthert M. Imidazoline binding sites and receptors in cardiovascular tissues. Gen Pharmacol 1999;32:17-22
10. Piletz JE, Sletten K. Non adrenergic imidazoline binding sites on human platelets. J Pharmacol Exp Ther 1993;267:1493-1502
11. 1-imidazoline receptors: definition, characterization, distribution and transmembrane signalling. Ann N Y Acad Sci 1995;763:22-42
12. 1-imidazoline binding sites. Neurochem Int 1997;30:17-23
13. Heemskerk FMJ, Dontenville M, Greney H, Vonthron C, Bousquet P. Evidence for the existence of imidazoline-specific binding sites in synaptosomal plasma membranes of the bovine brainstem. J Neurochem 1998;71:2193-2202
14. 1 imidazoline receptors to the cAMP pathway: studies with a high selective ligand, benazoline. Mol Pharmacol 2000;57:1142-51
15. 1-imidazoline receptors to diacylglyceride accumulation in PC12 rat pheochromocytoma cells. Mol Pharmacol 1996;49:668-75
16. 1-imidazoline receptor in PC12 pheochromocytoma cells activates protein kinases C, extracellular signal-regulated kinase (ERK) and c-jun N-terminal kinase (JNK). J Neurochem 2001;79:931-940
17. 1 receptor-induced activation of phosphatidylcholine-specific phospholipase C elicits mitogen-activated protein kinase phosphorylation in PC12 cells. Eur J Pharmacol 2001;415:117-25
18. Farsang C, Kapocsi J. Review: imidazoline receptors: from discovery to antihypertensive therapy (facts and doubts). Brain Res Bull 1999;49:317-31
19. Mitrovic V, Patyna W, Hüting J, Schlepper W. Haemodynamic and neurohormonal effects of moxonidine in patients with essential hypertension. Cardiovasc Drugs Ther 1991;5:967-72
20. 1-Imidazoline Receptor Agonist Moxonidine: a New Antihypertensive, 2nd edn. London: Royal Society of Medicine Press, 1996:49-77
21. + transport and intracellular pH in renal proximal tubule cells. Biochim Biophys Acta 1990;1024:173-8
22. Hamilton CA. The role of imidazoline receptors in blood pressure regulation. Pharmacol Ther 1992;54:231-48
23. Aparicio M, Dratwa M, el Esper N, Fillastre JP, Levaltier B, Lins R, Meyrier A, Mignon F, Ryckelnek JP, Sennesael J. Pharmacokinetics of rilmenidine in patients with chronic renal insufficiency and in hemodialysis patients. Am J Cardiol 1994;74:43A-59A
24. Genissel P, Bromet N, Fourtillan JB, Mignot A, Albin H. Pharmacokinetics of rilmenidine in healthy subjects. Am J Cardiol 1988;61:47D-53D
25. Guicheney P, Dausse JP, Meyer P. Relative affinities of S3341 and clonidine for the alpha1 and alpha2 adrenoceptors of the rat brain. J Pharmacol 1981;12:255-62
26. Albin H, Baldit C, Vincon G, Genissel P. Influence of food intake on the pharmacokinetics of rilmenidine (S3341) in the healthy subjects. 1st Symposium on Imidazoline Receptors, Heidelberg; 1986 (Abstr)
27. Genissel P, Bromet N, Fourtillan JB, et al. Pharmacokinetics of rilmenidine in healthy subjects. Am J Cardiol 1988;61:47D-53D
28. Passeron J, Guillet C. Time-lag to maximal response of hypertension to rilmenidine 1 mg per day. A multicenter ambulatory study. Presse Med 1992;21:2089-93
29. Morrison PJ, Corcoran C, Vivet P. Rilmenidine and vigilance. JAMA. 1990 (special issue July):27-28
30. Galley P, Manciet G, Hessel JL, Michel JP. Antihypertensive efficacy and acceptability of rilmenidine in elderly hypertensive patients. Am J Cardiol 1988;61(7):86D-90D
31. Luccioni R. Evaluation pharmaco-épidemiologique de la rilmenidine chez 18335 hypertendus. Presse Med 1995;24:1857-64
32. Fiorentini C, Guillet C, Guazzi M. Etude multicentrique en double aveugle comparant la rilmenidine 1 mg et l'hydrochlorothiazide 25 mg chez 244 patients. Arch Mal Cœur Vaiss 1989;82:39-46
33. Dallochio M, Gosse P, Fillastre JP, Grollier G, Morand P, Drici M, Corcoran C. Rilmenidine, a new antihypertensive agent, in the first-line treatment of essential hypertension. A multicenter double-blind study versus atenolol. Presse Med 1991;20:1265-71
34. Pelemans W, Verhaeghe J, Creytens G, Coupez G, van Dessel A, Opsomer M, Corcoran C. Efficacy and safety of rilmenidine in elderly patients: comparison with hydrochlorothiazide. The Belgian multicentre study group. Am J Cardiol 1994;74:51A-57A
35. Mpoy M, Vandeleene B, Ketelslegers JM, Lambert AE. Treatment of systemic hypertension in insulin-treated diabetes mellitus with rilmenidine. Am J Cardiol 1988;61:91D-94D
36. De Luca N, Izzo R, Fontana D, Iovino G, Argenziano L, Vecchione C, Trimarco B. Haemodynamic and metabolic effects of rilmenidine in hypertensive patients with metabolic syndrome X. A double-blind parallel study versus amlodipine. J Hypertens 2000;18:1515-22
37. Kannel WB. Ventricular hypertrophy as a risk factor: the Framingham experience. J Hypertens 1991;9(Suppl 2):S3-9
38. Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345-52
39. Cooper RS, Simmons BE, Castaner A, Ghali J, et al. Left ventricular hypertrophy is associated with worse survival independent of ventricular function and number of coronary arteries severely narrowed. Am J Cardiol 1990;65:441-5
40. Yurenev AP, Dyakonova HG, Novikov JD, et al. Management of essential hypertension in patients with different degrees of left ventricular hypertrophy: a multicenter study. Am J Hypertens 1992;5:182S-189S
41. Koren MJ, Ulin RJ, Laragh JH, Devereux RB. Reduction in left ventricular mass during treatment of essential hypertension is associated with improved prognosis. Am J Hypertens 1991;4:1A
42. Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998;97:48-54
43. Muiesan ML, Salvetti M, Rizzoni D, et al. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995;13:1091-95
44. Dahlöf B. Regression of left ventricular hypertrophy - are there differences between antihypertensive agents? Cardiology 1992;81:307-15
45. Schmieder RE, Markus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. JAMA 1996;275:1507-13
46. van Zwieten PA. The influence of antihypertensive drug treatment on the prevention and regression of left ventricular hypertrophy. Cardiovascular Res 2000;45;82-91
47. Sadowski Z, Szwed H, Kuch-Wocial A, et al. Regression of left ventricular hypertrophy in hypertensive patients after 1 year treatment with rilmenidine: a double-blind randomized, controlled (versus nifedipine) study. J Hypertens 1998;16 (Suppl 3):S55-62
48. Trimarco B, Rosiello G, Sarno D, et al. Effects of one-year treatment with rilmenidine on systemic hypertension-induced left ventricular hypertrophy in hypertensive patients. Am J Cardiol 1994;74:36A-42A
49. Trimarco B, Morisco C, Sarno D, et al. Rilmenidine in patients with left ventricular hypertrophy: beyond the reduction of left ventricular mass. J Cardiovasc Pharmacol 1995;26(Suppl 2):29-33
50. Farsang C, Zorándi A, Dienesné SzB. The antihypertensive effect of rilmenidine. The design and first results of the Hungarian multicentric study. Hypertonia és Nephrologia 1999;3:178-83 (in Hungarian)
51. Gardin JM. How reliable are serial echocardiographic measurements in detecting regression in left ventricular hypertrophy and changes in function? J Am Coll Cardiol 1999;34:1633-6
52. Quinones MA, Waggoner AD, Reduto LA, et al. A new simplified and accurate method for determining ejection fraction with two-dimensional echocardiography. Circulation 1981;64:744
53. Troy BL, Pombo J, Rackley ChE. Measurement of left ventricular wall thickness and mass by echocardiography. Circulation 1972;45:602
54. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10
55. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Circulation 1977;55:613-18
56. Lithell HO. Hyperinsulinaemia, insulin resistance and the treatment of hypertension. J Hypertens 1996;9:150S-154S
57. Kaan EC, Brückner R, Frohly P, et al. Effects of agmatine and moxonidine on glucose metabolism. Cardiovasc Risk Fact 1995;5(Suppl 1):19-27
58. Liebson PR, Grandits GA, Dianzumba S, et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the treatment of mild hypertension study (TOMHS). Circulation 1995;91:698-706
59. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, et al. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension. Comparison of six antihypertensive agents. Circulation 1997;95:2007-14
60. Devereux RB, Dahlöf B, Levy D, Pfeffer MA. Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension. (The PRESERVE trial). Am J Cardiol 1996;78:61-5
61. Dahlöf B, Devereux R, de Faire U, et al. Losartan intervention for endpoint reduction in hypertension (the LIFE study). Am J Hypertens 1997;10:705-13
62. Gosse P, Guez D, Gueret P, et al. Centralized echocardiogram quality control in a multicenter study of regression of left ventricular hypertrophy in hypertension. J Hypertens 1998;16:531-5
63. Sheridan DJ. Regression of left ventricular hypertrophy: what are ideal design features? Eur Heart J 1999;1 (Suppl P): P31-P34
64. Gottdiener JS, Livengood SV, Meyer PS, et al. Should echocardiography be performed to assess effects of antihypertensive therapy? Test-retest reliability of echocardiography for measurement of left ventricular mass and function. J Am Coll Cardiol 1995;25:424-30
65. Boudoulas H. Determination of left ventricular mass in clinical practice. J Heart Valve Dis 1997;6:222-7
66. Grandi AM, Vencio A, Barzizza F, et al. Effect of enalapril on left ventricular mass and performance in essential hypertension. Am J Cardiol 1989;63:1093-7
67. Agabiti-Rosei E, Ambrosioni E, Dal Palu C, et al. ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE study. J Hypertens 1995;13:1325-34
68. Genovesi-Ebert A, Marabotti C, Palombo C, et al. Effect of a new multifactorial antihypertensive on heart morphology and function in mild to moderate essential arterial hypertension. Eur Heart J 1992;13(Suppl A):45-8
69. Szlachcic J, Tuban JF, Vollmer C, et al. Effect of diltiazem on left ventricular mass and diastolic filling in mild to moderate hypertension. Am J Cardiology 1989;63:198-201
70. Hüting J, Mitrovic V, Thormann J, et al. Left ventricular mass and diastolic function in patients with essential hypertension under longterm clonidine monotherapy. Clin Cardiol 1991;14:134-40
71. Carey PA, Sheridon DJ, Cordone A, et al. Effect of indapamide on left ventricular hypertrophy in hypertension: a meta-analysis. Am J Cardiol 1996;77:17B-19B
72. Devereux RB, Palmieri V, Liu JE, et al. Progressive hyperthrophy regression with sustained pressure reduction in hypertension: The Losartan Intervention for Endpoint Reduction study. J Hypertens 2002;20:1445-50
73. Malmquist K, Kahan T, Edner M, et al. Regression of left ventricular hyperthrophy in human hypertension with irbesartan. J Hypertens 2001;19:1167-76
74. Lorell BH, Carabello BA. Left ventricular hypertrophy. Pathogenesis, detection and prognosis. Circulation 2000;102:470-9
75. Oh JK, Seward JB, Tajik AJ. The Echo Manual. Boston: Little Brown Co., 1994:47
76. Rakowski H, Appleton Ch, Chan K-L, et al. Canadian consensus recommendations for the measurement and reporting of diastolic dysfunction by echocardiogrpahy. J Am Soc Echocardiogr 1996;736-60
77. Borbás S, Lengyel M, Arnold C, et al. Left ventricular hypertension and diastolic function in 'white coat' hypertension. Hypertonia és Nephrologia 1997;1:39-42 (in Hungarian)
78. Dittrich HC, Adler J, Ong J, et al. Effects of sustained-release nicardipine on regression of left ventricular hypertrophy in systemic hypertension. Am J Cardiol 1992;69:1559-64
79. Betocchi S, Chiariello M. Effects of calcium antagonists on left ventricular structure and function. J Hypertens 1993;11(Suppl 1):533-7
80. Török E, Borbás S, Lengyel M, et al. Regression of cardiac hypertrophy in hypertensive patients by long-term treatment with isradipine. J Cardiovasc Pharmacol 1992;19(Suppl 3):S79-83
81. Palmieri V, Belle JN, DeQuattro V, et al. Relations of diastolic left ventricular filling to systolic chamber and myocardial contractility in hypertensive patients with left ventricular hypertrophy (the PRESERVE Study). Am J Cardiol 1999;84:558-62